{"id":"NCT01752634","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-14","primaryCompletion":"2014-05-12","completion":"2019-01-09","firstPosted":"2012-12-19","resultsPosted":"2020-05-13","lastUpdate":"2020-05-13"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Secukinumab (AIN457)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Secukinumab (AIN457) 75 mg s.c.","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 150 mg s.c.","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 300 mg s.c.","type":"EXPERIMENTAL"},{"label":"Placebo s.c.","type":"PLACEBO_COMPARATOR"}],"summary":"This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA despite current or previous NSAID, DMARD and/or anti-TNFÎ± therapy. An additional 4 years of long-term efficacy and safety data were collected during the post Week 52 period of the study.","primaryOutcome":{"measure":"Number of Participants Achieving American College of Rheumatology 20 (ACR20) Response Criteria","timeFrame":"Week 24","effectByArm":[{"arm":"Secukinumab (AIN457) 75 mg s.c.","deltaMin":29,"sd":null},{"arm":"Secukinumab (AIN457) 150 mg s.c.","deltaMin":51,"sd":null},{"arm":"Secukinumab (AIN457) 300 mg s.c.","deltaMin":54,"sd":null},{"arm":"Placebo s.c.","deltaMin":15,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0200"},{"comp":"OG001 vs OG003","p":"<0001"},{"comp":"OG002 vs OG003","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":76,"countries":["United States","Australia","Belgium","Canada","Czechia","Germany","Poland","Puerto Rico","Russia","Thailand","United Kingdom"]},"refs":{"pmids":["38446397","38268157","34795065","31801620","31203228","30526678","29880010","29409133","28968735","26135703"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":99},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Psoriatic arthropathy","Arthralgia","Diarrhoea"]}}